Serum levels of estradiol and follicle stimulating hormone,and vasomotor symptoms in Thai women receivingGnRH analogue before laparoscopic enucleationof endometriotic cysts
article
OA: diamond
CC0
Abstract
Background : GnRH analogue can suppress serum estradiol (E2) and follicle stimulating hormone (FSH) to menopause level before laparoscopic enucleation of endometriotic cysts. Objective : To study the levels of E2 and FSH, and vasomotor symptoms after GnRH analogue treatment in Thai women with endometriotic cysts. Materials and Methods : During January, 2006 - December, 2007. Sixty women diagnosed as having endometriotic cysts, aged 15 - 44 years, were recruited into the study. Leuprolide acetate 3.75 mg was given intramuscularly at one month interval for 3 months. Serum levels of E2 and FSH were tested at 0, 1, 2 and 3 months after GnRH analogue treatments. Thai version of Greene climacteric score was recorded at 0, 1, 2 and 3 months. Results : The median (25th percentile, 75th percentile) of serum E2 level decreased significantly from the baseline (0 months: 232.3 (82.0,446.2) pmol/L vs. 1 months : 18.4(0,44.9) pmol/L, 2 months: 31.7(0,58.6) pmol/L, 3 months: 0(0,54.2) pmol/L). The median (25th percentile, 75th percentile) of serum FSH level decreased significantly from the baseline at 1,2 and 3 months. (0 months: 4.8(3.1,7.0) IU/L vs. 1 months: 2.2(1.3,3.5) IU/L, 2 months 2.8 (1.8,5.2) ,3 months 3.0(2.8,4.9) IU/L). Only 8.3% of women required sedative medication for vasomotor symptoms relief. The mean vasomotor symptoms scores were significantly higher than the baseline at 2 and 3 months period (0 months: 14.5 vs. 2 months: 20.0 and 3 months: 20.2). Most women had amenorrhea at 3 months period (93.3%). Conclusion : Leuprolide acetate can suppress ovarian function after the first month of injection. Most women can stand the vasomotor symptoms. Amenorrhea was the most common menstrual patterns at 3 months after injection.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (10)
- Changing concepts of medical treatment of endometriosis via openalex
- Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis via openalex
- Efficacy of Gonadotropin-Releasing Hormone Agonist and an Extended-Interval Dosing Regimen in the Treatment of Patients with Adenomyosis and Endometriosis via openalex
- GnRH agonists and add‐back therapy: is there a perfect combination? via openalex
- Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up via openalex
- Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up*1 via openalex
- Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial via openalex
- Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. via openalex
- The Effects of Combining Norethindrone with a Gonadotropin-Releasing Hormone Agonist in the Treatment of Symptomatic Endometriosis via openalex
- W116864337 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK